Bacillus Calmette-Guérin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer
Background: Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy remains one of the most effective treatments for non-muscle invasive bladder cancer (NMIBC). However, a substantial proportion of patients fail to respond, and the precise mechanisms underlying BCG's therapeutic effects remain incompletely understood. While extracellular vesicles (EVs) can modulate a range of biological processes, their relevance in this context is also poorly understood. Methods: . Results: significantly potentiated the therapeutic efficacy of BCG in a syngeneic murine bladder cancer model. Conclusion: as critical intermediaries in the anti-tumor immune response and suggest their potential utility as mediators and/or predictive biomarkers for therapeutic efficacy. In summary, we propose a previously unrecognized mechanism of BCG immunotherapy mediated by EVs, establishing them as pivotal components of the immune signaling network driving effective treatment outcomes.
Authors
- Ryan D. Molony (ORCID: https://orcid.org/0000-0003-1547-1430)
- E. M. Messing
- Carlos Ortiz-Bonilla (ORCID: https://orcid.org/0000-0002-6949-6193)
- Hiroshi Miyamoto
- Yi-Fen Lee
Institutions
- University of Rochester Medical Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-04-13
- DOI
- https://doi.org/10.3389/fimmu.2026.1707754
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00